Form 4: First Tracks Biotherapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Daniel Faga, President, CEO and a Director of First Tracks Biotherapeutics, Inc., received 193,575 shares of common stock on August 15, 2026.
Summary
- Grant/award: acquired 193,575 Performance Stock Units on August 15, 2026; holds 440,485 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Daniel Faga — Director, Officer (President, CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-08-15 | Grant/award | Performance Stock Units | 193,575 | — | — | 440,485 |
Key Dates
| Date | Description |
|---|---|
| 2026-08-15 | Grant/award (193,575 shares) |
Keywords
insider transaction, Form 4, TRAX, First Tracks Biotherapeutics, Inc., neutral, Daniel Faga
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.